The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Progesterone Receptor Negative
Triple-Negative Breast Carcinoma
HER2/Neu Negative
Estrogen Receptor Negative
Stage IV Breast Cancer
Recurrent Breast Carcinoma

Interventions: Drug: Galunisertib
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2016-02-03

Last Posted Date: 2023-11-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 29

Registration Number: NCT02672475

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Therapy-Related Acute Myeloid Leukemia
Therapy-Related Myelodysplastic Syndrome
Myeloid Sarcoma
Secondary Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Vosaroxin

First Posted Date: 2016-01-18

Last Posted Date: 2024-05-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 42

Registration Number: NCT02658487

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Phase 1

Completed

Conditions: Myelofibrosis
Polycythemia Vera

Interventions: Drug: TGR-1202
Drug: ruxolitinib

First Posted Date: 2015-07-09

Last Posted Date: 2024-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 60

Registration Number: NCT02493530

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Mays Cancer Center at University of Texas Health San Antonio, San Antonio, Texas, United States
🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States

and more 2 locations

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Phase 3

Completed

Conditions: Malignant Head and Neck Neoplasm
Mucositis
Radiation-Induced Disorder

Interventions: Other: Educational Intervention
Other: Pain Therapy
Drug: Gabapentin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Oxycodone/Acetaminophen
Drug: Hydrocodone/Acetaminophen
Drug: Fentanyl
Drug: Ibuprofen
Drug: Magic Mouthwash

First Posted Date: 2015-06-24

Last Posted Date: 2021-02-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 79

Registration Number: NCT02480114

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Estrogen Receptor Positive
Stage IV Breast Cancer
Estrogen Receptor Negative
Progesterone Receptor Negative
Progesterone Receptor Positive
HER2/Neu Negative
Triple-Negative Breast Carcinoma

Interventions: Other: Biomarker Analysis
Drug: Enzalutamide
Other: Pharmacological Study
Drug: Taselisib

First Posted Date: 2015-05-29

Last Posted Date: 2022-08-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT02457910

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 9 locations

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

Phase 2

Completed

Conditions: Lung Carcinoma
Solitary Pulmonary Nodule
Cigarette Smoking Behavior

Interventions: Procedure: Computed Tomography
Radiation: fluorodeoxyglucose F-18
Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography
Procedure: Positron Emission Tomography (PET)

First Posted Date: 2015-05-19

Last Posted Date: 2022-10-19

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 46

Registration Number: NCT02448225

Locations: 🇺🇸
Tennessee Valley Health System Nashville, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers

Not Applicable

Terminated

Conditions: Cancer

Interventions: Other: Educational Intervention
Other: Follow-Up Care
Procedure: Psychosocial Assessment and Care
Other: Questionnaire Administration

First Posted Date: 2015-05-12

Last Posted Date: 2019-10-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 67

Registration Number: NCT02440737

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Meharry Medical College, Nashville, Tennessee, United States

Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

Not Applicable

Completed

Conditions: Oral Cavity Cancer
Oropharyngeal Cancer
Lymphedema
Fibrosis

Interventions: Other: LEF measures
Procedure: Technical measure

First Posted Date: 2015-04-09

Last Posted Date: 2021-03-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 118

Registration Number: NCT02412241

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

18F-FES PET/CT in Imaging Patients With Desmoid Tumors

Early Phase 1

Terminated

Conditions: Deep Fibromatosis/Desmoid Tumor
Familial Adenomatous Polyposis

Interventions: Drug: F-18 16 Alpha-Fluoroestradiol
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-03-02

Last Posted Date: 2019-10-03

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT02374931

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Phase 2

Terminated

Conditions: Stage IIIC Uveal Melanoma
Stage IIIB Uveal Melanoma
Stage IIIA Uveal Melanoma
Stage IV Uveal Melanoma

Interventions: Biological: Pembrolizumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-02-10

Last Posted Date: 2019-09-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 5

Registration Number: NCT02359851

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy